Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Abeona, abicipar, adeno, AEs, al, alanine, ALT, aminotransferase, ASGCT, BBA, BCVA, Bipartisan, bleb, Blueprint, BREXIT, brolucizumab, Carter, category, CCPA, cDNA, CMC, CMO, collateral, commensurate, constrained, content, corrupt, corticosteroid, counsel, credibility, CRO, CRT, delete, departure, derecognized, diagram, discomfort, donut, dual, Duchenne, easily, EC, Eric, exemplary, explicitly, Exudation, faricimab, FDCA, feedback, fill, gap, GDPR, GILTI, glycogen, Grishanin, hole, HumorFollowing, IBC, incapable, incentivize, indirect, Instance, Kymriah, landlord, landscape, laundering, length, lesioning, licensee, loan, lyse, mg, mode, moiety, myopathy, myotubular, Nightstar, nonemployee, OD, ODD, ornithine, OS, pegol, Pharm, pocket, port, Poster, predecessor, prednisone, prompted, purposefully, Redwood, repayment, retinopathy, Richard, RMAT, SAE, Sanfilippo, Sarepta, serotype, sinister, Solid, Spivey, supplanting, surrogate, syndrome, tapering, tenant, titer, transcarbamylase, UK, Ultragenyx, visit, Yescarta
Removed:
acquirer, adrenoleukodystrophy, aging, allege, alternate, anniversary, applying, ataxia, Avastin, backlash, bank, bio, Biotech, bluebird, budgeted, burst, calling, Canada, cancellation, cancer, capitalization, Cervarix, China, complementary, Composite, comprised, concurrent, consisting, convenient, convening, conventional, corrected, correction, CRVO, cure, debilitating, default, deferral, demonstrating, depict, derivation, dissolution, division, Dr, earn, element, ending, endorse, enforceability, ethical, exchanged, exhibited, experiment, experimental, expired, FFDCA, finalize, FluBlok, forfeiture, fragment, Friedreich, fusion, generalized, Germany, graph, hedging, hereof, HIV, humanized, hundred, hypothetical, Iconic, immunodeficiency, impacting, infect, innovative, insertion, insertional, invalidate, inventor, irrevocably, Israel, Japan, Leber, leukemia, lymphoid, managerial, metabolic, multiplied, murine, Neuropathy, Neurotech, OBA, objective, occasion, Ohr, operational, ophthalmologic, ophthalmology, Ophthotech, opposition, Parkinson, Pennsylvania, placement, preferentially, premium, priced, principle, promoter, prosecuted, prospectively, quantity, quickly, ratio, recommence, recruiting, recurring, reexamination, refundable, regulating, reinvestment, renewal, reorganization, researched, resigned, respiratory, retaining, reversing, Room, screening, sixty, speculative, Stanford, suitable, surviving, Switzerland, Therapeutix, thousand, threshold, toxicity, transitioned, undergo, Valeant, validated, voluntarily, volunteer, volunteered, voted, warranted, Washington, Zealand
Filing tables
Filing exhibits
ADVM similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statements on Form S-8 No. 333-223894, No. 333-218465, No. 333-211439, No. 333-203398, and No. 333-199296 |
| (2) | Registration Statement on Form S-3 No. 333-219890 |
of our report dated March 6, 2019, with respect to the consolidated financial statements of Adverum Biotechnologies Inc. included in this Annual Report (Form 10-K) of Adverum Biotechnologies Inc. for the year ended December 31, 2018.
/s/ Ernst & Young LLP
San Jose, California
March 6, 2019